Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men

TNO20 enrolled

Overview

Overweight increases the risk to develop chronic diseases including type-2 diabetes and cardiovascular disease. The low-grade inflammatory status often seen in overweight subjects is thought to play an important role in disease development. The purpose of this study is to determine the role of inflammation on glucose metabolism and insulin resistance. In this study the effect of the anti-inflammatory treatment diclofenac on markers of inflammation and on parameters of glucose metabolism will be studied.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

Conditions

Overweight Obesity Inflammation

Interventions

DiclofenacDRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Body Mass Index (BMI): 25.1 - 32.0 kg/m2 * Normal Dutch eating habits Exclusion Criteria: * diabetes, cardiovascular disease or hypertension * Not suitable to receive diclofenac treatment * Smoking * Extreme physical activity (more than 6 hours/week) * Reported slimming or medically prescribed diet

Locations (1)

TNO Quality of Life

Zeist, Netherlands

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.